Company Description
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers.
Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient’s treatment location, making them what we believe to be “off-the-shelf.” Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
We expect to report initial data on autoimmune indications from at least one of our Phase 1/1b trial or the basket IIT in the first half of 2025.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Fred Aslan, M.D. |
Contact Details
Address: 5505 Morehouse Drive, Suite 100 San Diego, CA 92121 United States | |
| Phone | (858) 267-4467 |
| Website | artivabio.com |
Stock Details
| Ticker Symbol | ARTV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001817241 |
| Employer ID | 86-3614316 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Fred Aslan, M.D. | President, Chief Executive Officer and Director |
| Neha Krishnamohan | Chief Financial Officer and Executive Vice President of Corporate Development |
| Christopher P. Horan | Chief Technical Operations Officer |
| Thorsten Graef, M.D., Ph.D. | Chief Medical Officer |
| Jennifer Bush. | Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer |
| Heather Raymon, Ph.D. | Senior Vice President of Research and Early Development |
| Brian Daniels, M.D. | Chairperson of the Board of Directors |
| Laura Bessen, M.D. | Director |
| Elizabeth Hougen | Director |
| Yong-Jun Huh | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 10, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 3, 2024 | DRS | [Cover] Draft Registration Statement |
| Nov 1, 2022 | RW | Filing |
| Jun 6, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 7, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 21, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 16, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 8, 2021 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 5, 2021 | D | Notice of Exempt Offering of Securities |